2
项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的临床试验A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) [Civacir(TM)] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
100 项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的临床结果
100 项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的转化医学
100 项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的专利(医药)
1
项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的文献(医药)2006-09-01·Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: Chasing windmills?
Communications
作者: Gary L. Davis
100 项与 Hepatitis C immune globulin (Biotest Pharmaceuticals) 相关的药物交易